23Apr 2021 by Melissa Slogan
WHAT HAVE WE LEARNED IN ONE YEAR OF COVAX?

WHAT HAVE WE LEARNED IN ONE YEAR OF COVAX?

News
WEEKLY COVID VACCINE RESEARCH UPDATE Friday, April 23, 2021 High-income country confirmed dose total: 4.7 billion Upper-middle-income country total: 1.5 billion Lower-middle-income country total: 732 million Low-income country total: 770 million COVAX total: 1.12 billion Total worldwide confirmed purchases of Covid-19 vaccines: 8.9 billion doses INSIGHTS What have we learned in one year of COVAX? Author: Andrea Taylor Launched as a global cross-organization collaboration only one month after the pandemic was declared, COVAX was built to facilitate global equity in the pandemic response. As COVAX passes the one-year mark this month, there are some early lessons and insights that can inform its further development and help us prepare for future crises. In terms of numbers, COVAX is short of the mark. Photo ops of government officials on the tarmac to…
Read More
16Apr 2021 by Melissa Slogan
THE GLOBAL PICTURE OF COVID-19 VACCINE APPROVALS

THE GLOBAL PICTURE OF COVID-19 VACCINE APPROVALS

News
WEEKLY COVID VACCINE RESEARCH UPDATE Friday, April 16, 2021 High-income country confirmed dose total: 4.7 billion Upper-middle-income country total: 1.5 billion Lower-middle-income country total: 731 million Low-income country total: 770 million COVAX total: 1.12 billion Total worldwide confirmed purchases of Covid-19 vaccines: 8.9 billion doses INSIGHTS The global picture of Covid-19 vaccine approvals Author: Blen Biru COVID-19 vaccines across the world have been produced and authorized for use with record speed. So far, 13 vaccines have received either limited or full regulatory approval. It’s important to note that the safety of the vaccines is continuously monitored even after limited and full regulatory approvals are granted. The recent post-approval regulatory revisions and suspensions of Oxford-AstraZeneca and J&J demonstrate the continuous monitoring efforts by regulatory bodies. To highlight the importance of regulatory…
Read More
09Apr 2021 by Melissa Slogan
WILL CHICKEN EGGS CHANGE THE COVID-19 VACCINE LANDSCAPE?

WILL CHICKEN EGGS CHANGE THE COVID-19 VACCINE LANDSCAPE?

News
WEEKLY COVID VACCINE RESEARCH UPDATE Friday, April 9, 2021 High-income country confirmed dose total: 4.6 billion Upper-middle-income country total: 1.5 billion Lower-middle-income country total: 721 million Low-income country total: 770 million COVAX total: 1.12 billion Total worldwide confirmed purchases of Covid-19 vaccines: 8.8 billion doses WEEKLY INSIGHTS Will chicken eggs change the Covid-19 vaccine landscape? Author: Andrea Taylor A promising new vaccine candidate is getting a flurry of attention this week, even in a very crowded landscape that includes 11 vaccines on the market and 50+ more in Phase 2 or 3 trials. The newcomer NDV-HXP-S vaccine, developed through collaborations between researchers at University of Texas at Austin, PATH, and Mount Sinai, among others, is a mouthful to say but the name captures the two reasons people are excited about it. NDV refers to the…
Read More
02Apr 2021 by Melissa Slogan
THE CURIOUS CASE OF UPPER-MIDDLE INCOME COUNTRIES

THE CURIOUS CASE OF UPPER-MIDDLE INCOME COUNTRIES

News
WEEKLY COVID VACCINE RESEARCH UPDATE FRIDAY, April 2, 2021 Data Updates High-income country confirmed dose total: 4.6 billion Upper-middle-income country total: 1.5 billion Lower-middle-income country total: 691 million Low-income country total: 670 million COVAX total: 1.12 billion Total worldwide confirmed purchases of Covid-19 vaccines: 8.6 billion doses Weekly Insights and Interesting Trends The curious case of upper-middle income countries Author: Andrea Taylor The global imbalance in Covid-19 vaccines is often framed in terms of wealthy versus poor countries. While it can be summed that way (wealthy countries do have the majority of doses, while low-income countries have almost none), this overlooks the experience of upper-middle income countries (UMICs), such as Brazil, Indonesia, and China. The challenges faced by UMICs are different than those faced by lower-middle and low-income countries. They…
Read More